Navigation Links
A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
Date:3/8/2013

tic variant of this enzyme.

"Tecarfarin was specifically designed not to be metabolized by any CYP enzymes, which means it may require less monitoring than warfarin. Some monitoring, according to experts, may still be needed to ensure patient compliance. Data from EMBRACE-AC trial showed that tecarfarin is a more effective OAC than warfarin in patients with a CYP2C9 genetic variant taking at least one CYP2C9 inhibitor despite close monitoring," said Dr Peter Milner , Executive Chairman of Armetheon and partner at AshHill Pharmaceutical Investments.  He added, "for approval of tecarfarin, we anticipate only one more pivotal clinical trial will be required which could be a 'real world', open label study involving about 2500 pre-defined patients."

Recent research indicates that patients with chronic renal dysfunction or failure have reduced or variable activity of CYP enzymes such as CYP2C9 and CYP3A4 as well as the transporter permeability glycoprotein (P-gp). This may explain warfarin's suboptimal performance in this patient population. Currently marketed novel non-monitored OACs (in particular, Factor Xa inhibitors) are eliminated via the kidney and most of them are metabolized via CYP3A4 enzymes in addition to interacting with the P-gp. This may explain the significant variability in anticoagulation response to the novel non-monitored OACs in patients with chronic renal dysfunction or failure.

"Genetic and other sources of variability in the drug metabolizing enzymes CYP3A4 and CYP2C9 or transport related proteins such a P-gp could lead to unpredictable variability in plasma levels of drugs that are metabolized/eliminated through these pathways, particularly if they are used with concomitant medications that may be inhibitors of these metabolic/elimination pathways," said Professor Leslie Z. Benet , former Chairman and Professor of Biopharmaceutical Sciences at University of
'/>"/>

SOURCE Armetheon, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
8. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS , December 24, 2014 /PRNewswire/ ... Research Report on Global Disposable Syringe Industry ... to its online business intelligence library. ... Global Disposable Syringe Industry is a professional ... Syringe market.  For overview analysis, the report ...
(Date:12/24/2014)... 2014   Assurex Health, a personalized medicine ... providers for behavioral health and chronic pain conditions, ... in equity financing from new and existing investors, ... and Chief Executive Officer. The financing ... Assurex Health,s GeneSight ®  products.  GeneSight,s ...
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
Breaking Medicine Technology:World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... Warner Chilcott plc (Nasdaq: WCRX ) announced today ... Inc. ("Par").  The Paragraph IV Certification Notice advises the Company of the ... generic version of the Company,s ASACOL 400 mg delayed release mesalamine product. ... ASACOL 400 mg, which ...
... RATON, Fla. , June 28 ... launch Anastrozole 1mg Tablets.  The U.S. Food and Drug Administration ... (ANDA) for this first time generic, which is being supplied ... Arimidex®, a billion dollar cancer drug marketed by AstraZeneca.  Breckenridge ...
Cached Medicine Technology:Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
(Date:12/25/2014)... The short film “Color of Honor” by ... of a true 9/11 hero, Welles Remy Crowther. It has ... 24 hours of Nuremberg International Short Film Festival and the ... Actress, screenwriter and director Luciana Lagana plays the mother ... her husband, Gregory Graham - Graham plays a ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... of Dollars, GENEVA, SWITZERLAND, Feb. 11 ... will begin negotiations,here on an historic international treaty ... massive global problem that undermines efforts to reduce,tobacco ... and terrorist,organizations, and costs governments billions in revenue., ...
... LONDON, February 11 , - New Solution ... Efficiency, Misys plc (FTSE: MSY.L), the global ... in Pakistan has gone live with Misys,Equation. The ... revenues,reduce risk and drive business efficiency through processing, ...
... 11 MedThink Communications, an,innovator in medical ... been retained by Salix Pharmaceuticals, Inc, in,Morrisville ... under development, an,orally disintegrating form of metoclopramide., ... market the orally disintegrating,metoclopramide tablet and will ...
... Technology Into its ... ... the developer of,Software Lens(TM) technology, today announced a strategic cooperation ... integrates,Dblur,s Software Lens(TM) technology into STMicroelectronics, sensor and,camera module products., ...
... of Web pages dedicated to disseminating breast cancer information, ... Houston have determined that while most breast cancer data ... Web pages featured inaccuracies and sites displaying complementary and ... false or misleading health information. , Published in ...
... rest of the cells in your body, your red blood ... when mammals began to evolve. Other vertebrates such as fish, ... are inactive. Losing the nucleus enables the red blood cell ... be transported in the blood and boosting our metabolism. ...
Cached Medicine News:Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 2Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 3Health News:Nations to Launch Negotiations on Treaty to Combat Illicit Tobacco Trade 4Health News:Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 2Health News:MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product 3Health News:Dblur Concludes Licensing Deal With STMicroelectronics 2Health News:Review of online breast cancer information encourages healthy skepticism for consumers 2Health News:How red blood cells nuke their nuclei 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: